These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 36175774)
1. The challenge of selecting tumor antigens for chimeric antigen receptor T-cell therapy in ovarian cancer. Ding H; Zhang J; Zhang F; Xu Y; Yu Y; Liang W; Li Q Med Oncol; 2022 Sep; 39(12):232. PubMed ID: 36175774 [TBL] [Abstract][Full Text] [Related]
2. CAR-T therapy for ovarian cancer: Recent advances and future directions. Xin Q; Chen Y; Sun X; Li R; Wu Y; Huang X Biochem Pharmacol; 2024 Aug; 226():116349. PubMed ID: 38852648 [TBL] [Abstract][Full Text] [Related]
3. Effective Targeting of TAG72 Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ Front Immunol; 2018; 9():2268. PubMed ID: 30510550 [TBL] [Abstract][Full Text] [Related]
4. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer. Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620 [TBL] [Abstract][Full Text] [Related]
5. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. Dagar G; Gupta A; Masoodi T; Nisar S; Merhi M; Hashem S; Chauhan R; Dagar M; Mirza S; Bagga P; Kumar R; Akil ASA; Macha MA; Haris M; Uddin S; Singh M; Bhat AA J Transl Med; 2023 Jul; 21(1):449. PubMed ID: 37420216 [TBL] [Abstract][Full Text] [Related]
6. Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer. Shen Y; Liu G; Zhang Q; Tian X; Ouyang L; Zhang L Immunol Lett; 2023 Mar; 255():1-9. PubMed ID: 36739093 [TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen receptor-T (CAR-T) cells targeting Epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model. Fu J; Shang Y; Qian Z; Hou J; Yan F; Liu G; Dehua L; Tian X J Vet Med Sci; 2021 Mar; 83(2):241-247. PubMed ID: 33328392 [TBL] [Abstract][Full Text] [Related]
8. CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy. Zhang XW; Wu YS; Xu TM; Cui MH Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979400 [TBL] [Abstract][Full Text] [Related]
9. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme. Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice. Li T; Wang J BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954 [TBL] [Abstract][Full Text] [Related]
11. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update. Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932 [TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment. Terlikowska KM; Dobrzycka B; Terlikowski SJ Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800608 [TBL] [Abstract][Full Text] [Related]
13. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer. Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915 [TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325 [TBL] [Abstract][Full Text] [Related]
15. CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer. Nasiri F; Farrokhi K; Safarzadeh Kozani P; Mahboubi Kancha M; Dashti Shokoohi S; Safarzadeh Kozani P Front Immunol; 2023; 14():1302307. PubMed ID: 38146364 [TBL] [Abstract][Full Text] [Related]
16. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors. Sun Z; Li R; Shen Y; Tan S; Ding N; Xu R; Wang X; Wei J; Liu B; Meng F J Hematol Oncol; 2022 Mar; 15(1):29. PubMed ID: 35303900 [TBL] [Abstract][Full Text] [Related]
17. SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy. Benard E; Casey NP; Inderberg EM; Wälchli S Scand J Immunol; 2020 Oct; 92(4):e12917. PubMed ID: 32557659 [TBL] [Abstract][Full Text] [Related]
18. Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against Ovarian Cancer. Leong L; Tan HL; Cua S; Yong KSM; Chen Q; Choo A Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936170 [TBL] [Abstract][Full Text] [Related]
19. Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1. Mun SS; Meyerberg J; Peraro L; Korontsvit T; Gardner T; Malviya M; Kyi C; O'Cearbhaill RE; Liu C; Dao T; Scheinberg DA Cancer Immunol Immunother; 2023 Nov; 72(11):3773-3786. PubMed ID: 37635172 [TBL] [Abstract][Full Text] [Related]
20. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Chen J; Hu J; Gu L; Ji F; Zhang F; Zhang M; Li J; Chen Z; Jiang L; Zhang Y; Shi R; Ma L; Jia S; Zhang Y; Zhang Q; Liang J; Yao S; Hu Z; Guo Z Cancer Immunol Immunother; 2023 Feb; 72(2):409-425. PubMed ID: 35925286 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]